Zhejiang-based Zhida Pharma has announced a licensing deal with Sweden-headquartered Vivesto AB (STO: VIVE), securing all rights to Vivesto’s EU-registered Apealea (paclitaxel micellar) in China. This agreement expands Zhida Pharma’s portfolio and introduces a novel treatment option for patients in China.
Apealea: A Cremophor-Free Paclitaxel Formulation for Ovarian Cancer
Apealea is the first Cremophor-free formulation of paclitaxel approved for use in combination with carboplatin for the treatment of ovarian cancer. This drug stands out as a patented, water-soluble, intravenously injectable formulation that offers significant advantages over traditional paclitaxel treatments. With Apealea, premedication requirements are reduced, such as the need for steroids, and the infusion time is shorter, enhancing the patient experience and potentially improving treatment outcomes.
Implications of the Licensing Deal
The licensing deal with Vivesto AB positions Zhida Pharma to bring Apealea to the Chinese market, providing a new therapeutic option for patients with ovarian cancer. This agreement not only strengthens Zhida Pharma’s presence in the oncology space but also highlights the company’s commitment to offering innovative and patient-friendly cancer treatments.-Fineline Info & Tech
